

Characteristic	Discovery cohort		Validation cohort			
	Atezolizumab treatment		Atezolizumab treatment		Chemotherapy treatment	
	R (11)	NR (9)	R (15)	NR (15)	R (20)	NR (20)
Age (years) Mean (Std. Deviation)	69.3 (+/-8.1)	61.8 (+/- 7.3)	71.9 (+/-12.1)	65.7 (+/9.1)	66.1 (+/-10.8)	64.0 (+/-9.7)
Sex, number (%)						
male	9 (82)	7 (78)	11 (73)	10 (67)	19 (95)	17 (85)
female	2 (18)	2 (22)	4 (27)	5 (33)	1 (5)	3 (15)
Race, number (%)						
white	11 (100)	9 (100)	13 (86.6)	12 (80)	14 (70)	16 (80)
Asian	0 (0)	0 (0)	0 (0)	2 (13)	2 (10)	3 (15)
other	0 (0)	0 (0)	1 (6.7)	1 (7)	0	0
unknown	0 (0)	0 (0)	1 (6.7)		4 (20)	1 (5)
LDH (u/L) Median (interquartile range)	198 (181, 225)	278 (169.5, 430.5)	204 (163, 379)	267.5 (176.3, 301.8)	183.5 (161.3, 227.8)	182 (151, 342)
Liver metastases, number (%)	3 (27)	4 (44)	0 (0)	7 (47)	NA	NA
ECOG score, number						
0	4	4	6	3	NA	NA
1	7	5	7	12	NA	NA
2	0	0	2	0	NA	NA